RepliCel Life Sciencesの資産のリターン
RepliCel Life Sciencesの資産のリターン は何ですか。
RepliCel Life Sciences, Inc.の資産のリターン は-52.42%です。
資産のリターン の定義は何ですか。
資産のリターンは 、企業の資産が収益を生み出す際の収益性を示します。純利益を平均総資産で除して計算されます。
The return on assets (ROA) tells you what the company can do with what it has, i.e. how many dollars of earnings they derive from each dollar of assets they control. It's a useful number for comparing competing companies in the same industry. The number will vary widely across different industries. Return on assets gives an indication of the capital intensity of the company, which will depend on the industry; companies that require large initial investments will generally have lower return on assets. ROAs over 5% are generally considered good.
TSXVのセクタHealth Careにおける資産のリターン の企業と比べるRepliCel Life Sciences
RepliCel Life Sciencesは何をしますか。
RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual's own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company's product candidates include RCT-01, which has completed Phase I clinical trials for the treatment of chronic tendinosis; RCS-01 that is in Phase 2 clinical trials to treat aging and sun damaged skin; and RCH-01, which is in Phase 2 clinical trials for the treatment of hair loss. It is also developing RCI-02, a dermal injection device. The company has a collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. for establishing a clinical research program to develop and commercialize RCS-01 and RCT-01; and collaboration and technology transfer agreement with Shiseido Company, Limited for establishing a clinical research program for RCH-01. It also has a collaboration research project agreement with the University of British Columbia to build a hair follicle cell data map. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada.
RepliCel Life Sciencesと類似の資産のリターン
- Cardiff Oncologyの資産のリターン は-52.69%です。
- Better Plant Sciencesの資産のリターン は-52.61%です。
- Zenith Mineralsの資産のリターン は-52.56%です。
- Midatech Pharma Plcの資産のリターン は-52.50%です。
- Mithra Pharmaceuticals SAの資産のリターン は-52.47%です。
- Octopus Robots SADの資産のリターン は-52.45%です。
- RepliCel Life Sciencesの資産のリターン は-52.42%です。
- Eat Beyond Globalの資産のリターン は-52.36%です。
- Passage Bio Incの資産のリターン は-52.29%です。
- AbraPlata Resourceの資産のリターン は-52.27%です。
- GeNeuro SA (Switzerland)の資産のリターン は-52.27%です。
- InspireMD Incの資産のリターン は-52.26%です。
- Amani Goldの資産のリターン は-52.25%です。